首页> 美国卫生研究院文献>BMJ Case Reports >Case Report: Successful treatment of Takayasu arteritis with rituximab as a first-line immunosuppressant
【2h】

Case Report: Successful treatment of Takayasu arteritis with rituximab as a first-line immunosuppressant

机译:病例报告:以利妥昔单抗为一线免疫抑制剂成功治疗高发性大动脉炎

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Takayasu arteritis is a rare large vessel vasculitis which has traditionally been treated with high-dose steroids. There have been a small number of publications where biological agents have been used to manage refractory cases. To the authors knowledge, there are no publications using biological agents in combination with steroids as a first-line treatment in Takayasu arteritis. In this publication, we document the case of Takayasu arteritis, in a 39-year-old woman, where rituximab was used in combination with steroids as a first-line agent in the setting of poorly controlled bipolar affective disorder.
机译:Takayasu动脉炎是一种罕见的大血管血管炎,传统上已用大剂量类固醇治疗。很少有出版物使用生物制剂处理难治性病例。据作者所知,还没有出版物使用生物制剂与类固醇结合作为高津动脉炎的一线治疗。在本出版物中,我们记录了一名39岁妇女中的Takayasu动脉炎的案例,其中利妥昔单抗与类固醇联合使用作为一线药物以控制双相情感障碍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号